E-Mail
IMAGE: Dr. Husam Abdel-Qadir, lead author of the paper and cardiologist at the Peter Munk Cardiac Centre and Women s College Hospital. view more
Credit: Photo: UHN
Toronto - New research from UHN s Peter Munk Cardiac Centre (PMCC) shows statins, commonly prescribed to lower cholesterol and reduce the risk of heart disease and stroke, may also protect the heart from damaging side-effects of early breast cancer treatment.
Published Jan. 6, 2021 in the
Journal of the American Heart Association, an observational study found women already taking statins and treated with either anthracyclines or trastuzumab were half as likely to be hospitalized or visit an Emergency Department for heart failure within five years after chemotherapy.
E-Mail
DALLAS, Jan. 6, 2021 Statins, common cholesterol-lowering medications, may protect women s hearts from damage caused during chemotherapy for early-stage breast cancer, according to new research published today in the
Journal of the American Heart Association, an open access journal of the American Heart Association. Two types of cancer medications, anthracyclines and trastuzumab, are effective treatments for many women with breast cancer, however, the risk of heart muscle damage has limited their use, particularly in women who are at higher risk for heart problems because of their age or other medical issues, said Husam Abdel-Qadir, M.D., Ph.D., lead author of the study, assistant professor of medicine at the University of Toronto s Institute of Health Policy, Management and Evaluation, and a cardiologist at Women s College Hospital and the Peter Munk Cardiac Centre, part of the University Health Network in Toronto.
Statins may protect the heart from damaging side-effects of early breast cancer treatment
New research from UHN s Peter Munk Cardiac Centre (PMCC) shows statins, commonly prescribed to lower cholesterol and reduce the risk of heart disease and stroke, may also protect the heart from damaging side-effects of early breast cancer treatment.
Published Jan. 6, 2021 in the
Journal of the American Heart Association, an observational study found women already taking statins and treated with either anthracyclines or trastuzumab were half as likely to be hospitalized or visit an Emergency Department for heart failure within five years after chemotherapy.
Our job is to protect the heart and ensure it has the greatest fighting chance to get through chemotherapy.